Holen Sie sich die Stockscreener-App
18.31
5.12%
0.94
Handel nachbörslich:
18.15
-0.16
-0.87%
Schlusskurs vom Vortag:
$17.37
Offen:
$18.215
24-Stunden-Volumen:
1.42M
Relative Volume:
0.71
Marktkapitalisierung:
$3.00B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-446.21M
KGV:
-5.1674
EPS:
-3.5434
Netto-Cashflow:
$-423.92M
1W Leistung:
+14.69%
1M Leistung:
-0.01%
6M Leistung:
-13.75%
1J Leistung:
+56.19%
1-Tages-Spanne:
$17.54
$18.57
1-Wochen-Bereich:
$16.05
$18.57
52-Wochen-Spanne:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
18.14 | 2.87B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Dyne Therapeutics (DYN) Seeks FDA Approval for Duchenne Muscular Dystrophy Treatment - GuruFocus
Dyne Therapeutics Announces Submission of Biologics License Application to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy - Investing News Network
Dyne submits biologics license application for DMD treatment - Investing.com
Experimental Duchenne treatment from Dyne heads to FDA - Stock Titan
Dyne spikes as late-stage trial for Duchenne therapy gets underway - MSN
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares - AOL.com
DYN stock gains as it gears up for accelerated approval of DMD therapy: Wall Street sees 140% upside - MSN
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
How Investors Are Reacting To Dyne Therapeutics (DYN) Launching Phase 3 FORZETTO Trial For DYNE-251 - Sahm
(DYN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Dyne Therapeutics (DYN) director buys 2,500 Common Stock shares - Stock Titan
DYN Stock Chart | DYNE THERAPEUTICS INC (NASDAQ:DYN) - ChartMill
Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission (DYN) - Seeking Alpha
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients - The Globe and Mail
United States Duchenne Muscular Dystrophy Therapeutics Market - openPR.com
A Look At Dyne Therapeutics (DYN) Valuation As Phase 3 FORZETTO Trial Marks Key Development Milestone - Yahoo Finance
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Dyne Therapeutics, Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Dyne Therapeutics (DYN) Launches Phase 3 FORZETTO Trial for Duch - GuruFocus
Dyne Therapeutics Launches Late-Stage Trial for DMD Therapy - Intellectia AI
Dyne stock spikes as Duchenne trial launches (DYN:NASDAQ) - Seeking Alpha
DYN: 2026 will focus on DMD and DM1 launches, confirmatory trials, and pipeline expansion - TradingView
DYN: 2026 targets commercial launches for DMD and DM1, with pipeline expansion and strong clinical data - TradingView
Dyne Therapeutics launches phase 3 trial for DMD treatment - Investing.com UK
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy Ahead of Planned BLA Submission for U.S. Accelerated Approval - Investing News Network
Dyne Therapeutics Initiates Phase 3 Trial of Potential Duchenne Muscular Dystrophy Treatment - Moomoo
Duchenne trial of z-rostudirsen tied to U.S. accelerated approval bid - Stock Titan
Dyne Therapeutics launches phase 3 trial for DMD treatment By Investing.com - Investing.com South Africa
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval - The Manila Times
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO - GlobeNewswire
MSN Money - MSN
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - Moomoo
DYN Maintained by Evercore ISI Group -- Price Target Lowered to $33 - GuruFocus
Janus Henderson reports 13.65M shares in Dyne Therapeutics (NASDAQ: DYN) - Stock Titan
T. Rowe Price (NASDAQ: DYN) holds 30.8M shares, a 18.7% stake - Stock Titan
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dyne Therapeutics Inc-Aktie (DYN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | Chief Commercial Officer |
May 13 '26 |
Sale |
18.36 |
228 |
4,186 |
154,353 |
| Kerr Douglas | Chief Medical Officer |
May 13 '26 |
Sale |
18.36 |
1,564 |
28,715 |
170,042 |
| Lucera Erick | Chief Financial Officer |
May 13 '26 |
Sale |
18.36 |
1,448 |
26,585 |
123,925 |
| Cox John | CEO & President |
May 13 '26 |
Sale |
18.36 |
3,311 |
60,790 |
370,834 |
1.49%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):